PR positivity was found in 54% of neuroendocrine tumors and in 36% of neuroendocrine carcinomas of the pancreas which is consistent with earlier studies describing PR positivity in 58-82% of pancreatic neuroendocrine tumors [51–53]. Here, PGR is linked to pancreatic endocrine carcinoma.